A synopsis of recent developments in antiglaucoma drugs.
Open-angle glaucoma is treated primarily with drugs, some of which have been used clinically for years. These drugs include: 1) cholinergic agonists that increase aqueous humor outflow, 2) adrenergic agonists and antagonist that affect both aqueous humor formation and outflow, and 3) carbonic anhydrase inhibitors that decrease aqueous humor formation. Several new classes of drugs are being tested for efficacy and mechanism of action. They include: 1) the D-isomer of timolol that reduces aqueous humor formation without producing adrenergic blockade, 2) dopaminergic agonists and antagonists, including bromocriptine and butyrophenones that reduce intraocular pressure, and 3) cannabinoids that reduce aqueous humor formation and increase outflow. In addition, several other types of drugs, such as prostaglandins, diuretics, Na+,K+-ATPase inhibitors, and adenyl cyclase stimulators are just now beginning to be studied.
D002186:Cannabinoids / Q000627:therapeutic use; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use; D018492:Dopamine Antagonists; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D013566:Sympathomimetics / Q000627:therapeutic use
D002186:Cannabinoids; D002257:Carbonic Anhydrase Inhibitors; D018492:Dopamine Antagonists; D013566:Sympathomimetics